Todos os estudos
AutorizadoFase II e Fase III (Integrado)Intervencionista

Fecal microbiota transplantation for primary sclerosing cholangitis - randomized study versus sham transplantation (FMT-SCLER).

This study is investigating a new treatment for a liver condition called Primary Sclerosing Cholangitis (PSC). It's looking at something called fecal microbiota transplantation, which involves introducing healthy gut bacteria from a donor into a patient. The aim is to see if this can improve liver function, specifically by reducing levels of a liver enzyme called ALP and also reducing levels of bilirubin. Participants will receive either the actual treatment (taken as capsules or as an enema) or a placebo (dummy treatment), and their health will be monitored over 48 weeks to understand how well the different treatments work and if they are safe.

Em resumo

Status
Autorizado
Fase
Fase II e Fase III (Integrado)
Patrocinador
Assistance Publique Hopitaux De Paris
Meta de inscrição
72
Iniciar
02 Dec 2025

Sobre o que é este estudo?

This study is about a health problem called Primary Sclerosing Cholangitis, often shortened to PSC. PSC is a long-term disease that slowly damages the bile ducts in your liver. Bile ducts are like small tubes that carry a digestive fluid called bile from your liver to your gut. When these ducts are damaged, bile can build up in your liver and cause problems.

Researchers are exploring a treatment called 'fecal microbiota transplantation' (FMT). This involves taking healthy gut bacteria from a donor and giving it to someone with a condition like PSC. The idea is that improving the mix of bacteria in your gut might help improve your liver health. In this study, some people will get the actual FMT treatment (either as capsules you swallow or as an enema), and others will get an inactive treatment called a 'placebo', which looks and feels the same but contains no active ingredients. This helps researchers work out if the FMT is truly making a difference.

The main goal of the study is to see if FMT can improve certain liver markers, specifically reducing levels of an enzyme called ALP and also bilirubin, over 48 weeks. They are also looking at other things like how patients feel, their quality of life, and any changes in other liver tests. This is a combined Phase II and Phase III study, meaning it's testing both if the treatment works and if it's safe and effective on a larger scale.

Pontos principais

  • This study is testing a new treatment called FMT for PSC.
  • FMT involves transplanting healthy gut bacteria.
  • It's a 'double-blind' study, meaning you might receive treatment or a placebo.
  • The main goals are to check liver health markers and safety over 48 weeks.
  • Participation involves regular tests and questionnaires.

Quem pode ser elegível?

To be part of this study, you need to be an adult, 18 years old or older. There is no upper age limit, meaning older adults can also take part.

The study is open to both men and women. If you have Primary Sclerosing Cholangitis, you might be suitable for this research.

However, the full details of who can and cannot join a study are much more specific than what's listed here. Your doctor would need to check many other things about your health to see if it's safe and appropriate for you.

Este estudo pode ser adequado para você?

Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.

  1. Você tem 18 anos ou mais?
  2. Do you have Primary Sclerosing Cholangitis?
  3. Você consegue comparecer a visitas e consultas regulares no hospital?
  4. Are you willing to potentially receive either the active treatment or a placebo?
  5. Are you comfortable with blood tests and liver scans?
Responda a todas as perguntas para ver o seu resultado.

O que envolve a participação?

If you decide to take part in this study, you would receive either the active fecal microbiota transplant treatment or a placebo (dummy treatment). The active treatment could be in the form of capsules you swallow or an enema. You wouldn't know which one you're getting, and neither would your study doctor, which is called 'double-blinded'.

Your health would be closely monitored over 48 weeks. This would involve regular visits where researchers would take blood tests to check your liver function (including ALP and bilirubin levels), and perform other assessments like liver scans (elastometry and magnetic resonance cholangiography). You would also be asked to fill out questionnaires to assess your symptoms, quality of life, and any changes in bowel activity if you have inflammatory bowel disease (IBD).

Throughout the study, researchers will be looking out for any side effects or changes in your overall health. The total duration of active participation and monitoring is at least 48 weeks, with some follow-up continuing beyond that for safety.

Riscos e benefícios potenciais

Participating in a study like this might offer some potential benefits, as you would receive a new and experimental treatment that could help improve your PSC, or contribute to finding a new treatment for others. However, there are also potential risks involved. The treatments are still being tested, and it's possible you could experience side effects, some of which might be unexpected or serious. You might also find the physical assessments and regular hospital visits time-consuming or uncomfortable. It's very important to remember that you are free to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Localizações (1)

Algumas localizações dos sites são aproximadas. Estamos melhorando isso — por favor, verifique com a equipe de teste antes de viajar.
  • —
    Não verificado
    França

Perguntas frequentes

What is Primary Sclerosing Cholangitis (PSC)?

PSC is a chronic liver disease that damages the small tubes (bile ducts) in your liver, which can lead to liver scarring and other problems.

What is fecal microbiota transplantation (FMT)?

FMT is a procedure where healthy gut bacteria are transferred from a donor into a patient, aiming to improve the patient's gut health.

Will I know if I'm getting the real treatment or a dummy treatment?

No, neither you nor your study doctor will know if you're getting the active treatment or the placebo. This is to ensure the study results are as fair as possible.

Por quanto tempo estarei envolvido no estudo?

Your direct participation and monitoring will last for at least 48 weeks, with some follow-up extending beyond that time.

What kind of tests will I have during the study?

You will have regular blood tests, liver scans, and fill out questionnaires about how you're feeling and your quality of life.

Como saber mais

Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.

Discussão

Discussão da comunidade

Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.